Review
Pharmacology & Pharmacy
Gregory L. Hundemer, Manish M. Sood
Summary: RAAS inhibitors are evidence-based treatments for various conditions, but can lead to hyperkalemia, which increases the risk for cardiovascular events. Managing hyperkalemia while maintaining the benefits of RAAS inhibitors is essential to prevent adverse outcomes.
PHARMACOLOGICAL RESEARCH
(2021)
Article
Cardiac & Cardiovascular Systems
Evelyne Meekers, Jeroen Dauw, Pieter Martens, Sebastiaan Dhont, Frederik H. Verbrugge, Petra Nijst, Jozine M. ter Maaten, Kevin Damman, Alexandre Mebazaa, Gerasimos Filippatos, Frank Ruschitzka, Wai Hong Wilson Tang, Matthias Dupont, Wilfried Mullens
Summary: The ADVOR trial demonstrated that acetazolamide has consistent diuretic effects across the entire range of renal function in patients with acute decompensated heart failure (ADHF). Acetazolamide increased the likelihood of successful decongestion, diuresis and natriuresis, especially in patients with lower estimated glomerular filtration rate (eGFR). Although acetazolamide was associated with a higher incidence of worsening renal function, it did not lead to adverse clinical outcomes.
EUROPEAN HEART JOURNAL
(2023)
Article
Urology & Nephrology
Daniel Murphy, Irina Chis Ster, Juan-Carlos Kaski, Lisa Anderson, Debasish Banerjee
Summary: This study aims to investigate the use of SZC for maximizing RAASi dosing in patients with advanced CKD and HF, assessing the impact of achieving target RAASi dosing on hospital admission rates and duration of stay, with the hope of reducing morbidity and improving quality of life.
Article
Cardiac & Cardiovascular Systems
Joseph B. Muhlestein, Jennifer Kammerer, Tami L. Bair, Kirk U. Knowlton, Viet T. Le, Jeffrey L. Anderson, Donald L. Lappe, Heidi T. May
Summary: This study found that in patients with heart failure, hyperkalaemia is associated with higher cardiovascular risk factors and increased risk of future major adverse cardiovascular events (MACE), while reduced use of renin-angiotensin-aldosterone system inhibitors is an independent predictor of future MACE.
Article
Health Care Sciences & Services
Christina Binder, Marko Poglitsch, Franz Duca, Rene Rettl, Theresa Marie Dachs, Daniel Dalos, Lore Schrutka, Benjamin Seirer, Luciana Camuz Ligios, Christophe Capelle, Roza Badr Eslam, Hong Qin, Christian Hengstenberg, Diana Bonderman
Summary: The study found that high plasma renin activity (PRA-S) is associated with poor prognosis in patients with heart failure with preserved ejection fraction (HFpEF), regardless of treatment with drugs that interact with the renin angiotensin aldosterone system (RAAS). Even with RAASi therapy, PRA-S levels remained predictive of all-cause death, possibly due to the hyperactivated RAAS leading to negative effects on the cardiovascular and renal system in HFpEF patients.
JOURNAL OF PERSONALIZED MEDICINE
(2021)
Article
Cardiac & Cardiovascular Systems
Bojan Vrtovec, Sabina Frljak, Gregor Poglajen, Gregor Zemljic, Andraz Cerar, Matjaz Sever, Francois Haddad, Joseph C. Wu
Summary: The study showed that CD34(+) cell therapy in patients with HFpEF resulted in improvements in E/e', NT-proBNP, exercise capacity, and local myocardial strain at the cell injection sites.
EUROPEAN JOURNAL OF HEART FAILURE
(2022)
Article
Cardiac & Cardiovascular Systems
Alexander C. Egbe, William R. Miranda, C. Charles Jain, Patrick S. Kamath, Renuka R. Katta, Kartik Andi, Ahmed Y. Goda, Heidi M. Connolly
Summary: This study retrospectively analyzed the postoperative changes in hepatic and renal function in adults with congenital heart disease (CHD) undergoing isolated heart transplant. The results showed that CHD patients experienced significant improvement in hepatic and renal function after the transplant. The study suggests that selected CHD patients may have favorable outcomes with isolated heart transplant despite reduced hepatic and renal function and preoperative hepatic fibrosis.
INTERNATIONAL JOURNAL OF CARDIOLOGY
(2022)
Article
Medicine, General & Internal
M. A. ap Pfeffer, B. Claggett, E. F. Lewis, C. B. Granger, L. Kober, A. P. Maggioni, D. L. Mann, J. J. V. McMurray, J. -L. Rouleau, S. D. Solomon, P. G. Steg, O. Berwanger, M. Cikes, C. G. De Pasquale, C. East, A. Fernandez, K. Jering, U. Landmesser, R. Mehran, B. Merkely, F. Vaghaiwalla Mody, M. C. Petrie, I. Petrov, M. Schou, M. Senni, D. Sim, P. van der Meer, M. Lefkowitz, Y. Zhou, J. Gong, E. Braunwald
Summary: Among patients with acute myocardial infarction, the use of Sacubitril-Valsartan did not significantly reduce the incidence of death from cardiovascular causes or incident heart failure compared to ramipril.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Cardiac & Cardiovascular Systems
Soeren J. Backhaus, Torben Lange, Elisabeth F. George, Kristian Hellenkamp, Roman J. Gertz, Marcus Billing, Rolf Wachter, Michael Steinmetz, Shelby Kutty, Uwe Raaz, Joachim Lotz, Tim Friede, Martin Uecker, Gerd Hasenfuss, Tim Seidler, Andreas Schuster
Summary: Real-time cardiac magnetic resonance (RT-CMR) exercise imaging can accurately diagnose HFpEF, providing a suitable noninvasive diagnostic alternative, which may be beneficial for routine clinical use pending further multicenter studies.
Article
Biochemistry & Molecular Biology
Konstantinos D. Rizas, Luisa Freyer, Nikolay Sappler, Lukas von Stuelpnagel, Peter Spielbichler, Aresa Krasniqi, Michael Schreinlechner, Felix N. Wenner, Fabian Theurl, Amira Behroz, Elodie Eiffener, Mathias P. Klemm, Annika Schneidewind, Martin Zens, Theresa Dolejsi, Ulrich Mansmann, Steffen Massberg, Axel Bauer
Summary: The study compared the efficacy of digital smart devices in detecting atrial fibrillation (AF) and found that digital screening technology more than doubled the detection rate of treatment-relevant AF compared to usual care. This technology has the potential for broad applicability and further studies are needed to assess if digital screening for AF leads to better treatment outcomes.
Article
Cardiac & Cardiovascular Systems
Saha Chatur, Muthiah Vaduganathan, Brian L. Claggett, Finnian R. Mc Causland, Akshay S. Desai, Pardeep S. Jhund, Rudolf A. de Boer, Adrian F. Hernandez, Silvio E. Inzucchi, Mikhail N. Kosiborod, Carolyn S. P. Lam, Felipe A. Martinez, Sanjiv J. Shah, Marc S. Sabatine, Lars Kober, Piotr Ponikowski, Bela Merkely, Magnus Petersson, Anna Maria Langkilde, John J. V. McMurray, Scott D. Solomon
Summary: This study aimed to investigate the safety and efficacy of continuing SGLT2 inhibitors in heart failure (HF) patients with a decline in estimated glomerular filtration rate (eGFR) below a certain threshold. The study found that patients with eGFR decline to <25 mL/min/1.73 m(2) had a higher risk of cardiovascular adverse events, but continuation of dapagliflozin treatment had no excess in safety outcomes and showed benefits in these patients.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
(2023)
Article
Medicine, General & Internal
Chun-Yen Chiang, Sheng-Chung Huang, Michael Chen, Jhih-Yuan Shih, Chon-Seng Hong, Nan-Chun Wu, Chung-Han Ho, Chia Chun Wu, Zhih-Cherng Chen, Wei-Ting Chang
Summary: This study examined the impact of renal impairment on treatment, echocardiographic parameters, and outcomes in AMI patients undergoing PCI. Patients with worse renal function were older, had more comorbidities, received less guideline-directed therapy, and had poorer cardiovascular outcomes.
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES
(2021)
Article
Cardiac & Cardiovascular Systems
Adriaan A. Voors, Kevin Damman, John R. Teerlink, Christiane E. Angermann, Sean P. Collins, Mikhail Kosiborod, Jan Biegus, Joao Pedro Ferreira, Michael E. Nassif, Mitchell A. Psotka, Jasper Tromp, Martina Brueckmann, Jonathan P. Blatchford, Afshin Salsali, Piotr Ponikowski
Summary: Empagliflozin, a SGLT2 inhibitor, caused an initial decline in renal function in patients with acute heart failure, but this effect was not evident after 90 days. Acute renal events were similar in both groups, and the clinical benefit of empagliflozin was consistent regardless of baseline renal function.
EUROPEAN JOURNAL OF HEART FAILURE
(2022)
Editorial Material
Cardiac & Cardiovascular Systems
Haider J. Warraich, Anju Nohria
Summary: This article discusses the relationship between worsening renal function and diuretic response in acute heart failure.
EUROPEAN JOURNAL OF HEART FAILURE
(2022)
Review
Biochemistry & Molecular Biology
Piotr Lagosz, Jan Biegus, Szymon Urban, Robert Zymlinski
Summary: Cardiorenal syndrome (CRS) is a complex and heterogeneous spectrum of symptoms that has posed challenges for cardiologists for many years. The coexistence of heart failure (HF) and deteriorated renal function adds to these challenges and is a strong predictor of poor outcomes. However, with the development of new renal assessment methods, we now have the opportunity to treat CRS more effectively than ever before. This review focuses on explaining the pathophysiology, recent advances, and current practices of monitoring renal function in patients with acute CRS, aiming to improve patient care and guide treatment strategies.
Article
Anesthesiology
G. Bozovic, S. Steen, T. Sjoberg, C. Schaefer-Prokop, J. Verschakelen, Q. Liao, P. Hoglund, R. Siemund, I. M. Bjorkman-Burtscher
ACTA ANAESTHESIOLOGICA SCANDINAVICA
(2016)
Article
Radiology, Nuclear Medicine & Medical Imaging
Birgitta Ramgren, Roger Siemund, Ola G. Nilsson, Peter Hoglund, Elna-Marie Larsson, Kasim Abul-Kasim, Isabella M. Bjorkman-Burtscher
Article
Cardiac & Cardiovascular Systems
Maya Landenhed, Doris Cunha-Goncalves, Faleh Al-Rashidi, Leif Pierre, Peter Hoglund, Bansi Koul
Article
Cardiac & Cardiovascular Systems
David Ansari, Peter Hoglund, Bodil Andersson, Johan Nilsson
JOURNAL OF THE AMERICAN HEART ASSOCIATION
(2016)
Article
Clinical Neurology
Ake Berggren, Lars Gustafson, Peter Hoglund, Aki Johanson
JOURNAL OF AFFECTIVE DISORDERS
(2016)
Article
Nutrition & Dietetics
Bodil Ohlsson, Peter Hoglund, Bodil Roth, Gassan Darwiche
NUTRITION RESEARCH
(2016)
Article
Surgery
Michael Akesson, Leena Lehti, Peter Hoglund, Per Akeson, Johan Wasselius
Article
Cardiac & Cardiovascular Systems
Henrik Bergenfeldt, Josef Stehlik, Peter Hoglund, Bodil Andersson, Johan Nilsson
JOURNAL OF HEART AND LUNG TRANSPLANTATION
(2017)
Article
Urology & Nephrology
Matthias Hellberg, Peter Hoglund, Philippa Svensson, Huda Abdulahi, Naomi Clyne
Article
Multidisciplinary Sciences
Dennis Medved, Mattias Ohlsson, Peter Hoglund, Bodil Andersson, Pierre Nugues, Johan Nilsson
SCIENTIFIC REPORTS
(2018)
Article
Nutrition & Dietetics
Clara Nilholm, Bodil Roth, Peter Hoglund, Kaj Blennow, Elisabet Englund, Oskar Hansson, Henrik Zetterberg, Bodil Ohlsson
NUTRITION RESEARCH
(2018)
Article
Cardiac & Cardiovascular Systems
Henrik Bergenfeldt, Lars H. Lund, Josef Stehlik, Bodil Andersson, Peter Hoglund, Johan Nilsson
JOURNAL OF HEART AND LUNG TRANSPLANTATION
(2019)
Article
Criminology & Penology
Claes Andersson, Zoran Vasiljevic, Peter Hoglund, Agneta Ojehagen, Mats Berglund
INTERNATIONAL JOURNAL OF OFFENDER THERAPY AND COMPARATIVE CRIMINOLOGY
(2020)
Article
Health Care Sciences & Services
Anna Axmon, Peter Hoglund, Gerd Ahlstrom
Meeting Abstract
Transplantation
Andreas Kronbichler, Johannes Leierer, Gisela Leierer, Gert Mayer, Alina Casian, Peter Hoglund, Kerstin Westman, David Jayne
NEPHROLOGY DIALYSIS TRANSPLANTATION
(2016)